Medscape March 14, 2024
Primary care clinicians have largely welcomed the arrival of Opill, the first over-the-counter (OTC) birth control pill from Perrigo, which will reach US pharmacy shelves this month. Although the medicine has a long track record of safe use, physicians and nurse practitioners may want to ready themselves to answer questions from patients about shifting to the option.
The switch to OTC status for the norgestrel-only contraceptive has the support of many physician groups, including the American Medical Association, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists (ACOG).
The end of the prescription-requirement removes a barrier to access for many women, especially those who lack insurance. But it also will take away a chief reason...
Today's Sponsors
Today's Sponsor